[go: up one dir, main page]

UY35823A - Profármacos de antagonista de nmda - Google Patents

Profármacos de antagonista de nmda

Info

Publication number
UY35823A
UY35823A UY0001035823A UY35823A UY35823A UY 35823 A UY35823 A UY 35823A UY 0001035823 A UY0001035823 A UY 0001035823A UY 35823 A UY35823 A UY 35823A UY 35823 A UY35823 A UY 35823A
Authority
UY
Uruguay
Prior art keywords
propharms
nmda antagonist
nmda
antagonist
ethanamine
Prior art date
Application number
UY0001035823A
Other languages
English (en)
Inventor
Balestra Michael
Nordvall Gunnar
Katharina Högdin
Per Jonas Malmborg
Weigelt Dirk
Bernstein Peter
Quirk Michael
Kers Annika
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY35823A publication Critical patent/UY35823A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Profármacos de un antagonista de NMDA, (S)-1-fenil-2-(piridin-2-il)etanamina, útil para el tratamiento de depresión (particularmente trastorno depresivo grave) o dolor; composiciones que los comprenden y métodos para fabricarlos.
UY0001035823A 2013-11-05 2014-11-05 Profármacos de antagonista de nmda UY35823A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361899903P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
UY35823A true UY35823A (es) 2015-04-30

Family

ID=51947383

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035823A UY35823A (es) 2013-11-05 2014-11-05 Profármacos de antagonista de nmda

Country Status (25)

Country Link
US (4) US9822075B2 (es)
EP (3) EP3564234B1 (es)
JP (4) JP6479834B2 (es)
KR (2) KR102336426B1 (es)
CN (2) CN111187202B (es)
AR (1) AR098319A1 (es)
AU (1) AU2014345407B2 (es)
CA (1) CA2928004C (es)
CY (1) CY1121749T1 (es)
DK (1) DK3066091T3 (es)
ES (3) ES2894903T3 (es)
HR (2) HRP20241784T1 (es)
HU (2) HUE045001T2 (es)
LT (1) LT3066091T (es)
MX (2) MX377276B (es)
PL (2) PL4001272T3 (es)
PT (1) PT3066091T (es)
RS (2) RS66369B1 (es)
RU (1) RU2695372C2 (es)
SI (1) SI3066091T1 (es)
SM (1) SMT202500023T1 (es)
TR (1) TR201909632T4 (es)
TW (1) TW201609653A (es)
UY (1) UY35823A (es)
WO (1) WO2015067923A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2894903T3 (es) 2013-11-05 2022-02-16 Astrazeneca Ab Profármacos antagonistas de NMDA
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
CN107578281B (zh) * 2017-08-31 2021-03-30 湖南大学 电子商务环境下用户优惠券行为预测方法及模型构建方法
KR20230026449A (ko) * 2020-06-23 2023-02-24 바이오하벤 테라퓨틱스 리미티드 (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형
WO2025137661A1 (en) * 2023-12-22 2025-06-26 Biohaven Therapeutics Ltd. Combination treatment of neurological disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7909514L (sv) * 1979-11-16 1981-05-17 Astra Laekemedel Ab Nya halofenyl-pyridyl-allylaminderivat
US4769466A (en) * 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
KR100259567B1 (ko) * 1992-04-03 2000-07-01 클래스 빌헬름슨 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1404324B2 (en) * 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
WO2005066122A2 (en) 2003-12-30 2005-07-21 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
CA2621847A1 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability
CN101246417B (zh) 2007-02-13 2010-09-29 艾威梯科技(北京)有限公司 音频数据流输入/输出无间断软件切换的方法和系统
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
EP2525830B1 (en) * 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8580850B2 (en) * 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
ES2894903T3 (es) 2013-11-05 2022-02-16 Astrazeneca Ab Profármacos antagonistas de NMDA

Also Published As

Publication number Publication date
KR20210148443A (ko) 2021-12-07
ES2894903T3 (es) 2022-02-16
ES2733344T3 (es) 2019-11-28
LT3066091T (lt) 2019-07-10
HRP20191159T1 (hr) 2019-10-04
US20160280647A1 (en) 2016-09-29
EP3066091B1 (en) 2019-04-03
RU2016119493A (ru) 2017-12-07
JP2021100950A (ja) 2021-07-08
EP3066091A1 (en) 2016-09-14
RS58991B1 (sr) 2019-08-30
KR102469167B1 (ko) 2022-11-22
TR201909632T4 (tr) 2019-07-22
WO2015067923A1 (en) 2015-05-14
US20180037550A1 (en) 2018-02-08
EP4001272C0 (en) 2024-11-13
AU2014345407A1 (en) 2016-06-02
MX2016005567A (es) 2016-07-21
US20210040039A1 (en) 2021-02-11
US20190152914A1 (en) 2019-05-23
TW201609653A (zh) 2016-03-16
CN111187202A (zh) 2020-05-22
CN105683180B (zh) 2020-01-21
RU2695372C2 (ru) 2019-07-23
AU2014345407B2 (en) 2018-10-18
PL4001272T3 (pl) 2025-02-10
KR20160079094A (ko) 2016-07-05
US9822075B2 (en) 2017-11-21
CA2928004C (en) 2022-04-12
JP6479834B2 (ja) 2019-03-06
PT3066091T (pt) 2019-07-11
AR098319A1 (es) 2016-05-26
EP4001272B1 (en) 2024-11-13
EP3564234B1 (en) 2021-09-29
RU2016119493A3 (es) 2018-06-29
HRP20241784T1 (hr) 2025-02-28
JP7234278B2 (ja) 2023-03-07
JP2016535098A (ja) 2016-11-10
CA2928004A1 (en) 2015-05-14
MX394633B (es) 2025-03-24
JP6633233B2 (ja) 2020-01-22
BR112016009949A8 (pt) 2020-04-14
DK3066091T3 (da) 2019-07-15
US10207994B2 (en) 2019-02-19
KR102336426B1 (ko) 2021-12-08
EP3564234A1 (en) 2019-11-06
HUE070532T2 (hu) 2025-06-28
JP2020055857A (ja) 2020-04-09
PL3066091T3 (pl) 2019-10-31
JP6856737B2 (ja) 2021-04-07
SMT202500023T1 (it) 2025-03-12
SI3066091T1 (sl) 2019-09-30
HUE045001T2 (hu) 2019-12-30
CN105683180A (zh) 2016-06-15
MX2020011946A (es) 2022-08-10
MX377276B (es) 2025-03-07
EP4001272A1 (en) 2022-05-25
CN111187202B (zh) 2025-01-21
RS66369B1 (sr) 2025-01-31
ES2999064T3 (en) 2025-02-24
US10815199B2 (en) 2020-10-27
JP2019081781A (ja) 2019-05-30
CY1121749T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CR20150462A (es) Inhibidores de erk y sus usos
UY35500A (es) Indazoles sustituidos con heteroarilo
NI201600071A (es) Compuestos de inhibidor de autotaxina
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150316A (es) Compuestos y sus métodos de empleo
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
NI201500140A (es) Compuestos y composiciones terapéuticos
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211215